DMAC vs JD · $157.4M cap vs P/E 7.6, rev $187.20B
DiaMedica Therapeutics Inc (DMAC) versus JD.com Inc Adr (JD) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
JD.com Inc Adr (JD) is a internet retail company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported JD revenue for 2025-12-31 was $187.20B. Net income was $3.31B. Revenue was up 17.9% from 2024-12-31 to 2025-12-31. JD currently screens at market cap $45.56B and trailing P/E 7.6.
DMAC currently screens at market cap $157.4M. JD currently screens at market cap $45.56B and trailing P/E 7.6.
Not investment advice. Open the DMAC and JD stock pages for the full models.
Not investment advice.